Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Evolocumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Repatha is and how it works Repatha is a medicine that lowers levels of 'bad' cholesterol, a type of fat, in the blood. Repatha contains the active substance evolocumab, a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body). Evolocumab is designed to attach to a substance called PCSK9 that affects the liver's ability to take in cholesterol. By attaching to, and mopping up PCSK9, the medicine increases the amount of cholesterol entering the liver and so lowers the level of cholesterol in the blood. What Repatha is used for Repatha is used in addition to your cholesterol lowering diet if you are: an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia). It is given: together with a statin or other cholesterol lowering medication, if the maximum dose of a statin does not lower levels of cholesterol sufficiently. alone or together with other cholesterol lowering medications when statins do not work well or cannot be used.
1
a child aged 10 years and older with a high cholesterol level in your blood because of a condition that runs in your family (heterozygous familial hypercholesterolaemia or HeFH). It is given alone or together with other cholesterol lowering treatments. an adult or a child aged 10 years and older with a high cholesterol level in your blood because of a condition that runs in your family (homozygous familial hypercholesterolaemia or HoFH). It is given together with other cholesterol lowering treatments. an adult with a high cholesterol level in your blood and established atherosclerotic cardiovascular disease (a history of heart attack, stroke or blood vessel problems). It is given: together with a statin or other cholesterol lowering medication, if the maximum dose of a statin does not lower levels of cholesterol sufficiently. alone or together with other cholesterol lowering medications when statins do not work well or cannot be used.
Repatha is used in patients who cannot control their cholesterol levels with a cholesterol lowering diet alone. You should stay on your cholesterol lowering diet while taking this medicine. Repatha can help prevent heart attack, stroke, and certain heart procedures to restore blood flow to the heart due to a build-up of fatty deposits in your arteries (also known as atherosclerotic cardiovascular disease). 2.
e Repatha
Do not use Repatha if you are allergic to evolocumab or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Repatha if you have liver disease. The needle cover of the glass pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions. In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future. Children and adolescents The use of Repatha has been studied in children 10 years of age and older being treated for heterozygous or homozygous familial hypercholesterolaemia. The use of Repatha has not been studied in children under 10 years of age. Other medicines and Repatha Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Repatha has not been tested in pregnant women. It is not known if Repatha will harm your unborn baby. It is not known whether Repatha is found in breast milk.
2
It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to stop taking Repatha, considering the benefit of breast-feeding to the baby and the benefit of Repatha to the mother. Driving and using machines Repatha has no or negligible influence on the ability to drive and use machines. Repatha contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodiumfree'. 3.
Repatha
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The recommended dose depends on the underlying condition: for adults with primary hypercholesterolaemia and mixed dyslipidaemia the dose is either 140 mg every two weeks or 420 mg once monthly. for children aged 10 years or older with heterozygous familial hypercholesterolaemia the dose is either 140 mg every two weeks or 420 mg once monthly. for adults or children aged 10 years or older with homozygous familial hypercholesterolaemia the recommended starting dose is 420 mg once monthly. After 12 weeks your doctor may decide to increase the dose to 420 mg every two weeks. If you also receive apheresis, a procedure similar to dialysis where cholesterol and other fats are removed from the blood, your doctor may decide to start you on a dose of 420 mg every two weeks to coincide with your apheresis treatment. for adults with established atherosclerotic cardiovascular disease (a history of heart attack, stroke or blood vessel problems) the dose is either 140 mg every two weeks or 420 mg once monthly. Repatha is given as an injection under the skin (subcutaneous). If your doctor prescribes a dose of 420 mg you must use three pre-filled pens because each pre-filled pen only contains 140 mg of medicine. After reaching room temperature, all injections should be given within a 30 minute period. If your doctor decides that you or a caregiver can give the injections of Repatha, you or your caregiver should receive training on how to prepare and inject Repatha correctly. Do not try to inject Repatha until you have been shown how to do it by your doctor or nurse. See the detailed "Instructions for Use" at the end of this leaflet for instructions about how to store, prepare, and give your Repatha injections at home. If using the pre-filled pen, place the correct (yellow) end of the pen on the skin before injecting. Before starting Repatha, you should be on a diet to lower your cholesterol. You should keep on this cholesterol lowering diet while taking Repatha. If your doctor has prescribed Repatha along with another cholesterol lowering medicine, follow your doctor's instructions on how to take these medicines together. In this case, please read the dosage instructions in the package leaflet of that particular medicine as well.
3
If you use more Repatha than you should Contact your doctor or pharmacist immediately. If you forget to take Repatha Take Repatha as soon as you can after the missed dose. Then, contact your doctor who will tell you when you should schedule your next dose, and follow the new schedule exactly as your doctor has told you. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Common (may affect up to 1 in 10 people) Flu (high temperature, sore throat, runny nose, cough and chills) Common cold, such as runny nose, sore throat or sinus infections (nasopharyngitis or upper respiratory tract infections) Feeling sick (nausea) Back pain Joint pain (arthralgia) Muscle pain Injection site reactions, such as bruising, redness, bleeding, pain or swelling Allergic reactions including rash Headache Uncommon (may affect up to 1 in 100 people) Hives, red itchy bumps on your skin (urticaria) Flu-like symptoms Rare (may affect up to 1 in 1,000 people) Swelling of the face, mouth, tongue, or throat (angioedema) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine. Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store 5.
Repatha
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2°C – 8°C). Do not freeze. Store in the original carton in order to protect from light. Your pre-filled pen may be left outside the refrigerator to reach room temperature (up to 25°C) before injection. This will make the injection more comfortable. After removal from the refrigerator, Repatha 4
may be stored at room temperature (up to 25°C) in the original carton and must be used within 1 month. Do not use this medicine if you notice it is discoloured or contains large lumps, flakes or coloured particles. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Repatha contains The active substance is evolocumab. Each SureClick pre-filled pen contains 140 mg of evolocumab in 1 mL of solution. The other ingredients are proline, glacial acetic acid, polysorbate 80, sodium hydroxide, water for injections. What Repatha looks like and contents of the pack Repatha is a solution which is clear to opalescent, colourless to yellowish, and practically free from particles. Each pack contains one, two, three or six single use SureClick pre-filled pens. Marketing Authorisation Holder Amgen Limited 216 Cambridge Science Park Milton Road Cambridge CB4 0WA United Kingdom Manufacturer Amgen Europe B.V. Minervum 7061 4817 ZK Breda The Netherlands Manufacturer Amgen Technology (Ireland) Unlimited Company Pottery Road Dun Laoghaire Co Dublin Ireland For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Amgen Limited Tel: +44 (0)1223 420305
5
This leaflet was last revised in March 2022. __________________________________________________________________________________ Instructions for use: Repatha single use SureClick pre-filled pen Guide to parts Before use
After use
Grey start button Expiry date Expiry date
Yellow window (injection complete) Window
Yellow safety guard (needle inside)
Medicine
Orange cap on
Yellow safety guard (needle inside)
Important: Needle is inside the yellow safety guard.
6
Orange cap off
Important Before you use the Repatha pre-filled pen, read this important information:
Do not freeze or use the Repatha pre-filled pen if it has been frozen.
Do not remove the orange cap from the Repatha pre-filled pen until you are ready to inject.
Do not use the Repatha pre-filled pen if it has been dropped on a hard surface. Part of the Repatha pre-filled pen may be broken even if you cannot see the break.
A 1. 2. 3. B
Step 1: Prepare Remove one Repatha pre-filled pen from the package. Carefully lift the pre-filled pen straight up out of the box. Put the original package with any unused pre-filled pens back in the refrigerator. Wait at least 30 minutes for the pre-filled pen to naturally reach room temperature before injecting. Do not try to warm the pre-filled pen by using a heat source such as hot water or microwave. Do not leave the pre-filled pen in direct sunlight. Do not shake the pre-filled pen. Do not remove the orange cap from the pre-filled pen yet. Inspect the Repatha pre-filled pen. Yellow safety guard (needle inside)
Orange cap on Window Medicine Make sure the medicine in the window is clear and colourless to slightly yellow. Check the expiration date. Do not use the pre-filled pen if medicine is cloudy or discoloured or contains large lumps, flakes, or particles. Do not use the pre-filled pen if any part appears cracked or broken. Do not use if the pre-filled pen has been dropped. Do not use the pre-filled pen if the orange cap is missing or not securely attached. Do not use the pre-filled pen if the expiration date has passed. In all cases, use a new pre-filled pen.
7
Gather all materials needed for your injection. C Wash your hands thoroughly with soap and water. On a clean, well-lit work surface, place the: New pre-filled pen. Alcohol wipes. Cotton ball or gauze pad. Plaster. Sharps disposal container.
D
Prepare and clean your injection site.
Upper arm Stomach area (abdomen)
Thigh Only use these injection sites: Thigh. Stomach area (abdomen), except for a 2 inch (5 centimetres) area around your belly button. Outer area of upper arm (only if someone else is giving you the injection). Clean the injection site with an alcohol wipe. Let your skin dry. Do not touch this area again before injecting. Choose a different site each time you give yourself an injection. If you need to use the same injection site, just make sure it is not the same spot on that site you used last time. Do not inject into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks.
8
A
Step 2: Get ready Pull the orange cap straight off, only when you are ready to inject. Do not leave the orange cap off for more than 5 minutes. This can dry out the medicine.
Orange cap It is normal to see a drop of liquid at the end of the needle or yellow safety guard. Do not twist, bend or wiggle the orange cap. Do not put the orange cap back onto the pre-filled pen. Do not put fingers into the yellow safety guard. Important: Do not remove the orange cap from the pre-filled pen until you are ready to inject. If you are unable to inject, please contact your healthcare provider.
9
Create a firm surface at the selected injection site (thigh, stomach, or outer areas of the upper arm), by using either the stretch method or the pinch method. Stretch method B
Stretch the skin firmly by moving your thumb and fingers in the opposite direction, creating an area about 2 inches (5 centimetres) wide. OR Pinch method
Pinch the skin firmly between your thumb and fingers, creating an area about 2 inches (5 centimetres) wide. Important: It is important to keep skin stretched or pinched while injecting.
10
A
Step 3: Inject Keep holding the stretched or pinched skin. With the orange cap off, put the yellow safety guard on your skin at 90 degrees. The needle is inside the yellow safety guard. Do not touch the grey start button yet.
Yellow Safety Guard (needle inside)
B
Firmly push down the pre-filled pen onto the skin until it stops moving.
Important: You must push all the way down but do not touch the grey start button until you are ready to inject. C
When you are ready to inject, press the grey start button. You will hear a click. "click"
11
D
Keep pushing down on the skin. Then lift your thumb while still holding the pre-filled pen on your skin. Your injection could take about 15 seconds. "click"
15 seconds
Window turns from clear to yellow when the injection is done. You may hear a second click. NOTE: After you remove the pre-filled pen from your skin, the needle will be automatically covered.
A
Step 4: Finish Discard the used pre-filled pen and orange needle cap.
Discard the used pre-filled pen and the orange cap in a sharps disposal container. Talk with your healthcare provider about proper disposal. There may be local guidelines for disposal. Keep the pre-filled pen and the sharps disposal container out of the sight and reach of children. Do not reuse the pre-filled pen. Do not recap the pre-filled pen or put fingers into the yellow safety guard. Do not recycle the pre-filled pen or sharps disposal container or throw them into household rubbish. B Examine the injection site. If there is blood, press a cotton ball or gauze pad on your injection site. Do not rub the injection site. Apply a plaster if needed.
12
The active substance in Repatha SureClick is evolocumab.
This leaflet reproduces the patient information leaflet approved for Repatha SureClick, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Hypercholesterolaemia and mixed dyslipidaemia
Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia, as an adjunct to diet:
• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
• alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Homozygous familial hypercholesterolaemia
Repatha is indicated in adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.
Established atherosclerotic cardiovascular disease
Repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:
• in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
• alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1.
Prior to initiating evolocumab, secondary causes of hyperlipidaemia or mixed dyslipidaemia (e.g., nephrotic syndrome, hypothyroidism) should be excluded.
Posology
Primary hypercholesterolaemia and mixed dyslipidaemia (including heterozygous familial hypercholesterolaemia)
Adults and paediatric patients (aged 10 years and over)
The recommended dose of evolocumab is either 140 mg every two weeks or 420 mg once monthly; both doses are clinically equivalent.
Homozygous familial hypercholesterolaemia in adults and paediatric patients aged 10 years and over
The initial recommended dose is 420 mg once monthly. After 12 weeks of treatment, dose frequency can be up-titrated to 420 mg once every 2 weeks if a clinically meaningful response is not achieved. Patients on apheresis may initiate treatment with 420 mg every two weeks to correspond with their apheresis schedule.
Established atherosclerotic cardiovascular disease in adults
The recommended dose of evolocumab is either 140 mg every two weeks or 420 mg once monthly; both doses are clinically equivalent.
Special populations
Elderly patients (age ≥ 65 years)
No dose adjustment is necessary in elderly patients.
Patients with renal impairment
No dose adjustment is necessary in patients with renal impairment (see section 5.2).
Patients with hepatic impairment
No dose adjustment is necessary in patients with mild hepatic impairment, see section 4.4 for patients with moderate and severe hepatic impairment.
Paediatric population
The safety and effectiveness of Repatha have not been established in paediatric patients with heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH) who are younger than 10 years old or in paediatric patients with other types of hyperlipidaemia.
Method of administration
Subcutaneous use.
Evolocumab is for subcutaneous injection into the abdomen, thigh or upper arm region. Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red, or hard.
Evolocumab must not be administered intravenously or intramuscularly.
Repatha 140 mg solution for injection in pre-filled pen
The 140 mg dose should be delivered using a single pre-filled pen.
The 420 mg dose should be delivered using three pre-filled pens administered consecutively within 30 minutes.
Repatha is intended for patient self-administration after proper training. Administration of evolocumab can also be performed by an individual who has been trained to administer the product.
For single use only.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hepatic impairment
In patients with moderate hepatic impairment, a reduction in total evolocumab exposure was observed that may lead to a reduced effect on LDL-C reduction. Therefore, close monitoring may be warranted in these patients.
Patients with severe hepatic impairment (Child-Pugh class C) have not been studied (see section 5.2). Evolocumab should be used with caution in patients with severe hepatic impairment.
Dry natural rubber
Repatha 140 mg solution for injection in pre-filled pen
The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
No interaction studies have been performed.
The pharmacokinetic interaction between statins and evolocumab was evaluated in the clinical trials. An approximately 20% increase in the clearance of evolocumab was observed in patients co-administered statins. This increased clearance is in part mediated by statins increasing the concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) which did not adversely impact the pharmacodynamic effect of evolocumab on lipids. No statin dose adjustments are necessary when used in combination with evolocumab.
No studies on pharmacokinetic and pharmacodynamics interaction between evolocumab and lipid-lowering medicinal products other than statins and ezetimibe have been conducted.
Pregnancy
There are no or limited amount of data from the use of Repatha in pregnant women.
Animal studies do not indicate direct or indirect effects with respect to reproductive toxicity (see section 5.3).
Repatha should not be used during pregnancy unless the clinical condition of the woman requires treatment with evolocumab.
Breast-feeding
It is unknown whether evolocumab is excreted in human milk.
A risk to breastfed newborns/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or discontinue/abstain from Repatha therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility
No data on the effect of evolocumab on human fertility are available. Animal studies did not show any effects on fertility endpoints at area under the concentration time curve (AUC) exposure levels much higher than in patients receiving evolocumab at 420 mg once monthly (see section 5.3).
Repatha has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The most commonly reported adverse reactions at the recommended doses are nasopharyngitis (7.4%), upper respiratory tract infection (4.6%), back pain (4.4%), arthralgia (3.9%), influenza (3.2%), and injection site reactions (2.2%). The safety profile in the homozygous familial hypercholesterolaemia population was consistent with that demonstrated in the primary hypercholesterolaemia and mixed dyslipidaemia population.
Tabulated list of adverse reactions
Adverse reactions reported in pivotal, controlled clinical studies, and spontaneous reporting, are displayed by system organ class and frequency in table 1 below using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Table 1. Adverse reactions
MedDRA system organ class (SOC)
Adverse reactions
Frequency category
Infections and infestations
Influenza
Common
Nasopharyngitis
Common
Upper respiratory tract infection
Common
Immune system disorders
Hypersensitivity
Common
Rash
Common
Urticaria
Uncommon
Nervous system disorders
Headache
Common
Gastrointestinal disorders
Nausea
Common
Skin and subcutaneous tissue disorders
Angioedema
Rare
Musculoskeletal and connective tissue disorders
Back pain
Common
Arthralgia
Common
Myalgia
Common
General disorders and administration site conditions
Injection site reactions1
Common
Influenza-like illness
Uncommon
1 See section Description of selected adverse reactions.
The safety profile was consistent between subjects with post-baseline LDL-C < 25 mg/dL (0.65 mmol/L) or < 40 mg/dL(1.03 mmol/L) compared to subjects with higher post-baseline LDL-C (≥ 40 mg/dL[1.03 mmol/L]), with median (Q1, Q3) Repatha exposure of 84.2 (78.1, 89.8) months in subjects who continued on Repatha and 59.8 (52.8, 60.3) months in subjects on placebo who switched to Repatha in an open-label extension study.
Description of selected adverse reactions
Injection site reactions
The most frequent injection site reactions were injection site bruising, erythema, haemorrhage, injection site pain, and swelling.
Paediatric population
The safety and effectiveness of Repatha have been established in paediatric patients with heterozygous and homozygous familial hypercholesterolaemia. A clinical study to evaluate the effects of Repatha was conducted in 158 paediatric patients aged ≥ 10 to < 18 years old with heterozygous familial hypercholesterolaemia. No new safety concerns were identified and the safety data in this paediatric population was consistent with the known safety profile of the product in adults with heterozygous familial hypercholesterolaemia. Twenty-six paediatric patients with homozygous familial hypercholesterolaemia have been treated with Repatha in clinical studies conducted in patients aged ≥ 10 to < 18 years. No difference in safety was observed between paediatric and adult patients with homozygous familial hypercholesterolaemia.
Elderly population
Of the 18,546 patients treated with evolocumab in double-blind clinical studies 7,656 (41.3%) were ≥ 65 years old, while 1,500 (8.1%) were ≥ 75 years old. No overall differences in safety or efficacy were observed between these patients and younger patients.
Immunogenicity
In clinical studies, 0.3% of patients (48 out of 17,992 patients) treated with at least one dose of evolocumab tested positive for binding antibody development. The patients whose sera tested positive for binding antibodies were further evaluated for neutralising antibodies and none of the patients tested positive for neutralising antibodies. The presence of anti-evolocumab binding antibodies did not impact the pharmacokinetic profile, clinical response, or safety of evolocumab.
The development of anti-evolocumab antibodies was not detected in clinical trials of paediatric patients treated with Repatha.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
No adverse effects were observed in animal studies at exposures up to 300-fold higher than those in patients treated with 420 mg evolocumab once monthly.
There is no specific treatment for evolocumab overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Repatha SureClick. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.